Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02572323 · ClinicalTrials.gov registry record · Phase 2
Phase II Trial of Tesamorelin for Cognition in Aging HIV-Infected Persons
A Phase 2 study, sponsored by University of California, San Diego.
- Completed
- Registry status
- Phase 2
- Development phase
- 73
- Enrollment target
NCT02572323 is a Phase 2 study that has completed, run by University of California, San Diego. The registered enrollment target is 73 participants.
The verdict
NCT02572323, a Phase 2 study, has completed, sponsored by University of California, San Diego.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 73 participants
- Enrollment target
Study Summary
The aim of this study is to test whether tesamorelin, in combination with a text-messaging application to help with motivation and adherence, will significantly improve memory and thinking in HIV.
Interventions
- DRUG Tesamorelin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 73 participants |
| Start Date | 2017-02-15 |
| Est. Completion | 2023-10-15 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02572323
The ClinicalTrials.gov registry entry for NCT02572323 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 73 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of California, San Diego, which has 775 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Tesamorelin is the first listed.
NCT02572323 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02572323 about?
NCT02572323 is a clinical study titled "Phase II Trial of Tesamorelin for Cognition in Aging HIV-Infected Persons". The aim of this study is to test whether tesamorelin, in combination with a text-messaging application to help with motivation and adherence, will significantly improve memory and thinking in HIV.
What is the current status of trial NCT02572323?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 73 participants. The study started on 2017-02-15. Estimated completion is 2023-10-15.
What interventions are being tested in trial NCT02572323?
The interventions under investigation include: Tesamorelin (DRUG).
Who is sponsoring clinical trial NCT02572323?
This trial is sponsored by University of California, San Diego, which has 775 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.